UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000050416
Receipt number R000057371
Scientific Title A prospective cohort study to explore effective treatment preventing respiratory function decline in asthmatic children with medium-dose inhaled corticosteroid therapy.
Date of disclosure of the study information 2023/02/25
Last modified on 2025/02/10 10:57:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A prospective cohort study to explore effective treatment preventing respiratory function decline in asthmatic children with medium-dose inhaled corticosteroid therapy.

Acronym

A prospective cohort study to explore effective treatment preventing respiratory function decline in asthmatic children with medium-dose inhaled corticosteroid therapy.

Scientific Title

A prospective cohort study to explore effective treatment preventing respiratory function decline in asthmatic children with medium-dose inhaled corticosteroid therapy.

Scientific Title:Acronym

A prospective cohort study to explore effective treatment preventing respiratory function decline in asthmatic children with medium-dose inhaled corticosteroid therapy.

Region

Japan


Condition

Condition

Bronchial asthma

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study will explore what treatment can prevent respiratory function decline and improve long-term prognosis in asthmatic children whose respiratory function decline despite moderate-dose ICS treatment.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Changes in respiratory function by therapeutic agent

Key secondary outcomes

1. changes in asthma control
2. Biomarker changes
3. confirmation of the presence or absence of growth suppression


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

6 years-old <=

Age-upper limit

16 years-old >

Gender

Male and Female

Key inclusion criteria

1) Asthmatic children between 6 and 16 years of age who are treated by Step 3 long-term management of Japanese guideline.
2) Those whose FEV1, FEV1/FVC, and V50 have been measured at least once a year, and at least 3 times in the last 2 years

Key exclusion criteria

1) Patients who are treating or have ever treated by biologics
2) Those who have requested to opt out of this study
3) Those who are deemed by the Principal Investigator or Principal Investigator to be inappropriate for participation in this study.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Takahiro
Middle name
Last name Nishida

Organization

National Mie Hospital

Division name

Department of Pediatrics and Allergy

Zip code

514-0125

Address

357 Osato-Kubota-cho, Tsu City, Mie

TEL

059-232-2531

Email

t_nishida0930@yahoo.co.jp


Public contact

Name of contact person

1st name Takahiro
Middle name
Last name Nishida

Organization

National Mie Hospital

Division name

Department of Pediatrics and Allergy

Zip code

514-0125

Address

357 Osato-Kubota-cho, Tsu City, Mie

TEL

0592322531

Homepage URL


Email

t_nishida0930@yahoo.co.jp


Sponsor or person

Institute

National Mie Hospital

Institute

Department

Personal name



Funding Source

Organization

Environmental Restoration and Conservation Agency

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

National Center for Child Health and Development
Sagamihara National Hospital
National Shimoshizu Hospital
Showa University School of Medicine
National Hospital Organaization Minami Wakayama Medical Center

Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Mie Hospital Ethics board

Address

357 Osato-Kubota-cho, Tsu City, Mie

Tel

0592322531

Email

t_nishida0930@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 12 Month 28 Day

Date of IRB

2023 Year 01 Month 05 Day

Anticipated trial start date

2023 Year 01 Month 05 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Prospective observational study


Management information

Registered date

2023 Year 02 Month 22 Day

Last modified on

2025 Year 02 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000057371